Gen­Script drops a mod­est in­vest­ment in­to its sup­ply ca­pac­i­ty as busi­ness booms

New Jer­sey’s Gen­Script an­nounced the open­ing of a 50,000-square-foot fa­cil­i­ty for au­to­mat­ed gene syn­the­sis and plas­mid pro­duc­tion ser­vices near its Pis­cat­away head­quar­ters Tues­day. The ex­pan­sion will en­sure high-qual­i­ty, fast turn­around on prod­ucts need­ed for new vac­cines, ther­a­peu­tics and syn­thet­ic bi­ol­o­gy in­no­va­tions.

“We all know that the geopo­lit­i­cal sit­u­a­tion is rapid­ly chang­ing at this point, ob­vi­ous­ly don’t want to speak too much to that … but ob­vi­ous­ly it’s im­por­tant for our clients,” se­nior glob­al project man­ag­er Ray Miller said in a call with End­points News. “This is one way for Gen­Script to mit­i­gate some of that risk.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER